Guggenheim Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $75
بريستول مايرز سكويب كو
Bristol-Myers Squibb Company BMY | 0.00 |
Guggenheim analyst Seamus Fernandez maintains Bristol-Myers Squibb (NYSE:
BMY) with a Buy and raises the price target from $72 to $75.
